IRON TRIANGLE PARTNERS LP
Q1 2025 Form 13-F
COS COB, CONNECTICUT
CIK 0001779763
· CRD 302077
· SEC-registered investment adviser
$634.4M Reported Value Total
IRON TRIANGLE PARTNERS LP reports 7 total accounts under management (AUM). There are 7 discretionary accounts valued at $1,263,073,089, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered
Discretionary Manager
Private funds (Form ADV)
2 funds
· $359.6M gross asset value
Hedge Fund: $359.6M
Source: Form ADV filed 2026-03-24
Reported value
$634.4M
Quarter over quarter
-3.9%
Holdings
27
Top-10 concentration
53.6%
Key People
Form ADV owners & control persons
Kevin Thomas Molloy
LIMITED PARTNER
Michael John O'Brien
CHIEF OPERATING OFFICER, CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2025 13F record
Q1 2025 13F filing summary
| Period of report | March 31, 2025 |
|---|---|
| Filed | May 15, 2025 |
| Form | 13F-HR |
| Reported value | $634.4M |
| Positions | 27 |
| Change in reported value | -30.2% |
| New positions | 12 |
| Exited positions | 7 |
| Position turnover | 55.9% |
| Top-10 concentration | 53.6% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q4 2025 13F
Filed Feb 17, 2026
|
27 | $874.7M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
25 | $703.3M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
26 | $651.2M |
|
Q1 2025 13F
Filed May 15, 2025
|
27 | $634.4M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
22 | $908.4M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
24 | $721.8M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
24 | $983.7M |
|
Q1 2024 13F
Filed May 15, 2024
|
28 | $976.3M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
26 | $772.9M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
23 | $684.2M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
22 | $748.1M |
|
Q1 2023 13F
Filed May 15, 2023
|
27 | $693.2M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
26 | $557.8M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
27 | $572.0M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
24 | $771.2M |
|
Q1 2022 13F
Filed May 16, 2022
|
28 | $840.7M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
25 | $717.7M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
26 | $696.8M |
|
Q2 2021 13F
Filed Aug 16, 2021
|
26 | $970.8M |
|
Q1 2021 13F
Filed May 17, 2021
|
27 | $786.5M |
5 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q1 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | DVA DAVITA INC | $48.9M | 7.71% |
| 2 | CAH CARDINAL HEALTH INC | $41.3M | 6.52% |
| 3 | ABBV ABBVIE INC | $40.4M | 6.37% |
| 4 | TEVA TEVA PHARMACEUTICAL INDS LTD | $34.1M | 5.37% |
| 5 | BSX BOSTON SCIENTIFIC CORP | $33.5M | 5.28% |
| 6 | GMED GLOBUS MED INC | $31.6M | 4.98% |
| 7 | THC TENET HEALTHCARE CORP | $28.2M | 4.44% |
| 8 | PODD INSULET CORP | $27.8M | 4.39% |
| 9 | AZN ASTRAZENECA PLC | $27.7M | 4.36% |
| 10 | ONC BEIGENE LTD | $26.6M | 4.2% |
| 11 | GH GUARDANT HEALTH INC | $25.6M | 4.03% |
| 12 | A AGILENT TECHNOLOGIES INC | $24.4M | 3.84% |
| 13 | MMSI MERIT MED SYS INC | $24.3M | 3.83% |
| 14 | NVST ENVISTA HOLDINGS CORPORATION | $21.3M | 3.35% |
| 15 | DOCS DOXIMITY INC | $20.9M | 3.29% |
| 16 | ALNY ALNYLAM PHARMACEUTICALS INC | $17.7M | 2.78% |
| 17 | AHCO ADAPTHEALTH CORP | $17.5M | 2.76% |
| 18 | TWST TWIST BIOSCIENCE CORP | $16.6M | 2.62% |
| 19 | ARGX ARGENX SE | $16.5M | 2.6% |
| 20 | NBIX NEUROCRINE BIOSCIENCES INC | $16.2M | 2.56% |
Values as reported on the Q1 2025 Form 13F. Every position is in the holdings table below.